Find and Pitch Jounalists, Get Your Story Covered

Tags: ursodiol therapy,UDCA treatment,PBC medication options,Ocaliva (obeticholic acid),second-line PBC treatments,cholestatic liver disease management,antimitochondrial antibody treatment,liver transplantation PBC,PBC symptom management,autoimmune liver disease therapy antibody therapy, B cells, drug development, immunotherapy, monoclonal antibodies Bispecific Antibodies DLBCL Therapeutic Potential

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Oxford Drug Design achieves in vivo validation for novel cancer treatment - 17 days ago Antag Therapeutics secures €80 million in weight loss therapy financing - about 2 months ago Arcellx to present positive data on multiple myeloma treatments - 3 months ago European Commission grants orphan drug designation for Vivet’s VTX-806 - 5 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results - about 1 month ago STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 6 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 10 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 12 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - over 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - about 2 months ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 5 months ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - 10 months ago Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer - 10 months ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases - 2 months ago STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - 2 months ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	A win for Apellis, a setback for Astellas - 2 months ago STAT+: Potential competition for RSV prophylactic Beyfortus - 4 months ago Regeneron is interested in obesity treatments that combat muscle loss - 12 months ago
6	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - 2 months ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - 4 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 7 months ago Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category - 11 months ago Astellas’ science chief on the leap into new technologies - 12 months ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - over 1 year ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 3 months ago STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 11 months ago STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans - about 1 year ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - about 1 year ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts Biologic License Application for Biosimilar Denosumab - 3 months ago TAK-279 Demonstrates Improvements in ACR 20 Response for Psoriatic Arthritis - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
9	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Regenerative Medicine Advanced Therapy Designation for OBX-115 - 5 months ago GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - 6 months ago
10	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK - 5 months ago

Journalists covering Arxx Therapeutics